PMID- 33852653
OWN - NLM
STAT- MEDLINE
DCOM- 20210426
LR  - 20220629
IS  - 1980-5322 (Electronic)
IS  - 1807-5932 (Print)
IS  - 1807-5932 (Linking)
VI  - 76
DP  - 2021
TI  - The novel fibrosis index at diagnosis may predict all-cause mortality in patients 
      with antineutrophil cytoplasmic antibody-associated vasculitis without 
      substantial liver diseases.
PG  - e2501
LID - 10.6061/clinics/2021/e2501 [doi]
LID - e2501
AB  - OBJECTIVES: Antineutrophil cyto plasmic antibody-associated vasculitis (AAV) is a 
      fatal disease. Currently, predictors of mortality due to AAV are based on the 
      distribution of organ involvement. The novel fibrosis index (NFI) is an index 
      composed of laboratory results that reflect the degree of liver fibrosis. This 
      study aimed to evaluate whether NFI can predict poor outcomes in patients with 
      AAV without substantial liver disease. METHODS: A total of 210 patients with 
      immunosuppressive drug-naive AAV were retrospectively reviewed. NFI was 
      calculated as follows: NFI=(serum bilirubin x (alkaline phosphatase)2)/(platelet 
      countx(serum albumin)2). NFI cut-off was set at 1.24 (the highest quartile). Poor 
      outcomes were defined as all-cause mortality, relapse, and end-stage renal 
      disease (ESRD). RESULTS: During the median 34.5 months of follow-up, 21 patients 
      (10%) died, 72 patients (34.3%) relapsed, and 38 patients (18.1%) had ESRD due to 
      AAV progression. The median calculated NFI was 0.61, and it was higher in AAV 
      patients with all-cause mortality than in those without mortality, but the 
      difference was not statistically significant (1.26 vs. 0.59). AAV patients with 
      NFI at diagnosis >/=1.24 exhibited a significantly lower cumulative patient 
      survival rate than those with NFI at diagnosis <1.24 (p=0.002). Multivariate Cox 
      hazard model analysis showed that NFI at diagnosis >/=1.24 was an independent 
      predictor of all-cause mortality in AAV (hazard ratios [HR] 2.850, 95% confidence 
      interval [CI] 1.026, 7.910). CONCLUSIONS: NFI >/=1.24, which may be an independent 
      predictive marker for all-cause mortality in AAV patients without substantial 
      liver disease.
FAU - Pyo, Jung Yoon
AU  - Pyo JY
AUID- ORCID: 0000-0002-1866-6885
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
FAU - Ahn, Sung Soo
AU  - Ahn SS
AUID- ORCID: 0000-0002-9002-9880
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
FAU - Lee, Lucy Eunju
AU  - Lee LE
AUID- ORCID: 0000-0002-0897-661X
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
FAU - Choi, Gwang-Mu
AU  - Choi GM
AUID- ORCID: 0000-0001-8569-2197
AD  - Department of Medicine, Yonsei University College of Medicine, Seoul, Republic of 
      Korea.
FAU - Song, Jason Jungsik
AU  - Song JJ
AUID- ORCID: 0000-0003-0662-7704
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, Republic of Korea.
FAU - Park, Yong-Beom
AU  - Park YB
AUID- ORCID: 0000-0003-4695-8620
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, Republic of Korea.
FAU - Lee, Sang-Won
AU  - Lee SW
AUID- ORCID: 0000-0002-8038-3341
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210409
PL  - United States
TA  - Clinics (Sao Paulo)
JT  - Clinics (Sao Paulo, Brazil)
JID - 101244734
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
SB  - IM
MH  - *Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
MH  - Antibodies, Antineutrophil Cytoplasmic
MH  - Fibrosis
MH  - Humans
MH  - *Liver Diseases
MH  - Retrospective Studies
PMC - PMC8009064
COIS- No potential conflict of interest was reported.
EDAT- 2021/04/15 06:00
MHDA- 2021/04/27 06:00
PMCR- 2021/01/01
CRDT- 2021/04/14 17:19
PHST- 2020/10/08 00:00 [received]
PHST- 2021/02/11 00:00 [accepted]
PHST- 2021/04/14 17:19 [entrez]
PHST- 2021/04/15 06:00 [pubmed]
PHST- 2021/04/27 06:00 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - S1807-5932(22)00113-2 [pii]
AID - cln_76p1 [pii]
AID - 10.6061/clinics/2021/e2501 [doi]
PST - epublish
SO  - Clinics (Sao Paulo). 2021 Apr 9;76:e2501. doi: 10.6061/clinics/2021/e2501. 
      eCollection 2021.